REFERENCES
- Colls BM, Harvey VJ, Skelton L, et al. Results of the surveillance policy of stage I non-seminomatous germ cell testicular tumors. Br J Urol 1992; 70: 423–428.
- Bredael JJ, Vugrin D, Whitmore WF. Selected experience with surgery and combination chemotherapy in the treatment of nonseminomatous testis tumors. J Urol 1983; 129: 985–988.
- Peckham ML, Barrett A, Husband JE, Hendry WF. Orchiectomy alone in testicular stage I nonseminomatous germ cell tumours Lancet 1982; 2: 678–680.
- Johnson DW, Lo RK, von Eschenbach AC: Surveillance alone for patients with clinical stage I non-seminomatous germ cell tumors of the testis. Preliminary results. J Urol 1984; 131: 491–493.
- Raghavan D, Colls B, Levi J, et al. Surveillance for stage I non-seminomatous germ cell tumours of the testis: the optimal protocol has not yet been defined. Br J Urol 1988; 61: 522–526.
- Sogani PC, Fair WR. Surveillance alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis (NSGCT). Semin Urol 1988; 6: 53–56.
- Thompson PI, Nixon J, Harvey VJ. Disease relapse in patients with stage I nonseminomatous germ cell tumor of the testis on active surveillance. J Clin Oncol 1988; 6: 1597–1603.
- Hoeltl W, Pont J, Honetz N, Marberger M. Treatment decisions for stage I non-seminomatous germ cell tumours based on the risk factor ‘vascular invasion’. Br J Urol 1992; 69: 83–87.
- Klepp O, Olsson AM, Henrikson H, et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: Multivariate analysis of a prospective multicenter study (SWENOTECA). J Clin Oncol 1990; 8: 509–518.
- Horwich A, Norman A, Fisher C, Hendry WF, Nicholls J, Dearnaley DP. Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. J Urol 1994; 151: 72–78.
- Mostofi FK, Sobin LH. Histological typing of testis tumours in International Histological Classification of tumors. No. 16. Geneva, Switzerland: World Health Organization, 1977: 1–39.
- Einhorn LH. Treatment of testicular cancer: A new and improved model. J Clin Oncol 1990; 8: 1777–1781.
- Studer EU, Fey MF, Calderoni A, Kraft R, Mazzucchelli L, Sonntag RW. Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-semonomatous testicular cancer. Eur Urol 1993; 23: 444–449.
- Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): Modifications of technique and impact on ejaculation. J Urol 1993; 149: 237–243.
- Pizzocaro G. Management of stage I non-seminoma: rationale for lymphadenectomy. In: Horwich A, ed. Testicular cancer, Investigation and Management. New York: Chapman & Hall, 1991: 167–172.
- Richie JP. Clinical stage I testicular cancer: The role of modified retroperitoneal lymphadenectomy. J Urol 1990; 144: 1160–1163.
- Klepp O, Olsson AM, Ous S, Nilsson S, Høisæther P-Å, Tveter K. Early clinical stages of nonseminomatous testis cancer. Evaluation of the primary treatment and follow-up procedures of the SWENOTECA project. Scand J Urol Nephrol 1991; 25: 179–190.
- McLeoid DG, Weiss RB, Stablein DM, et al. Staging relationships and outcome in early stage testicular cancer: A report from the testicular cancer intergroup study. J Urol 1991; 145: 1178–1183.
- Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989; 7: 387–391.
- Hoskin P, Dilly S, Easton D, Horwich A, Hendry W, Peckham MJ. Prognostic factors in stage I non-seminomatous germ-cell testicular tumours managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. J Clin Oncol 1986; 4: 1031–1036.
- Horwich A, Brada M, Nicholls J, et al. Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours. Eur J Cancer Clin Oncol 1989; 25: 177–184.
- Aass N, Fosså SD, Theodorsen L, Norman N. Prediction of long-term gonadal toxicity after standard treatment for testicular cancer. Eur J Cancer 1991; 27: 1087–1091.
- Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rørth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ cell tumors. Lancet 1991; 338: 359–363.
- Nichols CR, Breeden ES, Loehrer PJ, Williams SD, Einhorn LH. Secondary leukemia associated with a conventional dose of etoposide: Review of serial germ cell tumor protocols. J Nat Cancer Inst 1993; 85: 36–40.